Polymyositis Market Size was USD 114 million in 2023, Anticipated to grow at a rapid CAGR by 2034

The Polymyositis market size was valued approximately USD 114 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034). DelveInsight’s comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Polymyositis landscape.

In 2023, the Polymyositis market was largest in the US among the 7 major markets (7MM), valued at approximately USD 86 million, and is projected to grow at a CAGR of 15.8% during the forecast period. Within the EU, Germany had the highest market size at around USD 6 million, while Spain reported the smallest at approximately USD 2 million. In Japan, the market was valued at USD 9 million in 2023, with an expected CAGR of 16.4% by 2034.

According to DelveInsight’s analysis, the total diagnosed prevalent cases of Polymyositis in the 7 major markets (7MM) were estimated at approximately 80,000 in 2023. The US had the highest prevalence, with nearly 37,000 cases, which are expected to rise by 2034. In Europe, Germany reported the largest number of diagnosed cases at around 9,000, followed by France with approximately 7,000 cases, while Spain had the lowest prevalence at about 3,000 cases. In Japan, there were around 12,000 diagnosed cases, accounting for roughly 16% of the total 7MM cases in 2023.

In 2023, the United States recorded approximately 14,000 male cases and 22,000 female cases of Polymyositis. DelveInsight’s analysis also indicates that in Japan, the condition was more prevalent among females, with roughly 9,000 cases, compared to about 3,000 cases in males during the same year.

DelveInsight’s report “Polymyositis Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of the Polymyositis landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines Polymyositis market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To Know in detail about the Polymyositis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Polymyositis Market Forecast

Some of the key facts of the Polymyositis Market Report:

• The anticipated introduction of new therapies, including Anifrolumab (SAPHNELO), PF-06823859, and Enpatoran (M5049), among others, is expected to drive changes in the total market size of Polymyositis in the coming years.
• Key Polymyositis Companies: AstraZeneca, Pfizer, Argenx, Immunoforge Co. Ltd., Chester Oddis, Kezar Life Sciences, Inc., Mallinckrodt, Merck KGaA, Astellas Pharma Inc, Genentech, Immunoforge Co. Ltd., Pfizer, Bristol-Myers Squibb, and others
• Key Polymyositis Therapies: SAPHNELO (Anifrolumab), Dazukibart (PF-06823859), Efgartigimod, PF1801, tocilizumab, KZR-616, Adrenocorticotropic Hormone Gel, M5049 high dose, Tacrolimus, Rituximab, Froniglutide, PF-06823859, Abatacept subcutaneous, and others
• The Polymyositis epidemiology based on gender analyzed that Polymyositis affects females more as compared to males
• The Polymyositis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Polymyositis pipeline products will significantly revolutionize the Polymyositis market dynamics.

Polymyositis Overview

Polymyositis is a rare, chronic inflammatory muscle disease characterized by muscle weakness and inflammation. It belongs to a group of diseases called inflammatory myopathies and primarily affects the skeletal muscles, which are responsible for movement.

Get a Free sample for the Polymyositis Market Forecast, Size & Share Analysis Report:  

https://www.delveinsight.com/report-store/polymyositis-market

Key Factors Driving The Polymyositis Market:

• Rising Prevalence of Idiopathic Inflammatory Myopathies (IIMs): Increasing incidence of autoimmune and inflammatory disorders continues to elevate the demand for effective polymyositis treatments.
• Advancements in Diagnostic Techniques: Improved use of autoantibody panels, MRI, and muscle biopsy technologies enables faster and more accurate diagnosis, supporting timely treatment adoption.
• Expansion of Immunomodulatory and Biologic Therapies: Growing availability of corticosteroids, immunosuppressants, IVIG, and emerging biologics fuels market growth by offering broader therapeutic options.
• Increased Awareness and Clinical Research Activity: Enhanced understanding of disease mechanisms and ongoing clinical trials for novel therapies contribute to innovation and pipeline expansion.
• Aging Population and Higher Autoimmune Susceptibility: Rising geriatric population more prone to autoimmune conditions drives an increasing patient pool and long-term treatment need.

Polymyositis Epidemiology

The Polymyositis epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Polymyositis Epidemiology Segmentation:

The Polymyositis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Polymyositis
• Prevalent Cases of Polymyositis by severity
• Gender-specific Prevalence of Polymyositis
• Diagnosed Cases of Episodic and Chronic Polymyositis

Download the report to understand which factors are driving Polymyositis epidemiology trends @ Polymyositis Epidemiology Forecast

Recent Developments In The Polymyositis Treatment Landscape: 

• In May 2025, Teva Pharmaceuticals, in collaboration with Alvotech, received FDA approval for SELARSID™, a biosimilar to Stelara®. This approval enhances their portfolio in immunomodulatory therapies applicable to polymyositis treatment approaches.
• In January 2025, RESTEM announced that the FDA has granted Fast Track designation for its Restem-L program, which utilizes umbilical cord outer lining stem cells (ULSCs) to treat Polymyositis and Dermatomyositis (PM/DM), now classified as Idiopathic Inflammatory Myopathy (IIM). This follows the program’s recent Orphan Drug Designation for IIM.
• In December 2024, RESTEM, a clinical-stage biotech company focused on developing next-generation, off-the-shelf cell therapies to regulate the immune system, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its umbilical cord outer lining stem cells (ULSCs) program for treating Polymyositis (PM) and Dermatomyositis (DM).
• In November 2024, RESTEM announced Phase 1 trial results for its innovative umbilical cord outer lining-derived stem cells (ULSCs) program targeting adults with Polymyositis (PM) and Dermatomyositis (DM), now recognized by the FDA as Idiopathic Inflammatory Myopathy (IIM), a rare orphan disease with significant unmet medical needs.

Polymyositis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Polymyositis market or expected to get launched during the study period. The analysis covers Polymyositis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Polymyositis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Polymyositis Therapies and Key Companies

• SAPHNELO (Anifrolumab): AstraZeneca
• Dazukibart (PF-06823859): Pfizer
• Efgartigimod: Argenx
• PF1801: Immunoforge Co. Ltd.
• tocilizumab: Chester Oddis
• KZR-616: Kezar Life Sciences, Inc.
• Adrenocorticotropic Hormone Gel: Mallinckrodt
• M5049 high dose: Merck KGaA
• Tacrolimus: Astellas Pharma Inc
• Rituximab: Genentech
• Froniglutide: Immunoforge Co. Ltd.
• PF-06823859: Pfizer
• Abatacept subcutaneous: Bristol-Myers Squibb

Discover more about therapies set to grab major Polymyositis market share @ Polymyositis Treatment Landscape

Polymyositis Market Drivers

• Rising prevalence of autoimmune and inflammatory myopathies increasing demand for effective therapies.
• Advancements in diagnostic tools, including autoantibody testing, MRI, and muscle biopsy, enabling earlier and accurate diagnosis.
• Expansion of treatment options, including corticosteroids, immunosuppressants, IVIG, and emerging biologics.
• Growing awareness among clinicians and patients, improving diagnosis rates and treatment adoption.
• Increasing research and clinical trials for novel therapies, fueling market innovation and pipeline growth

Polymyositis Market Barriers

• Limited availability of curative treatments; current therapies mainly manage symptoms and slow disease progression.
• High treatment costs, particularly for biologics and long-term immunosuppressive therapies, restricting patient access.
• Side effects and safety concerns associated with existing treatments, impacting patient compliance.
• Low disease awareness in certain regions, leading to delayed diagnosis and underreporting.
• Small patient populations in some markets may limit commercial incentives for major pharmaceutical investments.

Scope of the Polymyositis Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Polymyositis Companies: AstraZeneca, Pfizer, Argenx, Immunoforge Co. Ltd., Chester Oddis, Kezar Life Sciences, Inc., Mallinckrodt, Merck KGaA, Astellas Pharma Inc, Genentech, Immunoforge Co. Ltd., Pfizer, Bristol-Myers Squibb, and others
• Key Polymyositis Therapies: SAPHNELO (Anifrolumab), Dazukibart (PF-06823859), Efgartigimod, PF1801, tocilizumab, KZR-616, Adrenocorticotropic Hormone Gel, M5049 high dose, Tacrolimus, Rituximab, Froniglutide, PF-06823859, Abatacept subcutaneous, and others
• Polymyositis Therapeutic Assessment: Polymyositis current marketed and Polymyositis emerging therapies
• Polymyositis Market Dynamics: Polymyositis market drivers and Polymyositis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Polymyositis Unmet Needs, KOL’s views, Analyst’s views, Polymyositis Market Access and Reimbursement 

To know more about Polymyositis companies working in the treatment market, visit @ Polymyositis Clinical Trials and Therapeutic Assessment